Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 13/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692167 | 0.93 | CYP2D6 (0.70) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL2381838 | 0.92 | CYP2D6 (0.67) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL16431003 | 0.91 | CYP2D6 (0.78) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL16600547 | 0.88 | CYP2D6 (0.66) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL25809456 | 0.86 | CYP2D6 (0.63) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL23968815 | 0.82 | CYP2D6 (0.87) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL4136438 | 0.82 | CYP2D6 (0.61) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL2789446 | 0.80 | CCR8 (0.73) | — | |
| SCHEMBL13309474 | 0.80 | CHRM2 (0.64) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL9851657 | 0.79 | CYP2D6 (0.81) | CYP2D6CHRM2CHRM3CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | CYP2D6 1049/4885CHRM2 78/4885CHRM3 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.